Molecular characterization of head and neck cancer: How close to personalized targeted therapy?

Molecular Diagnosis and Therapy

Volumn 16, Issue 4, 2012, Pages 209-222

  Worsham, Maria J ^a   Ali, Haythem ^b   Dragovic, Jadranka ^b   Schweitzer, Vanessa P ^a  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Cetuximab; DNA methylation modulators; Epidermal growth factor receptor target; Head and neck cancer; Human papillomavirus type 16 oncogene protein e7 target

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; LAPATINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; WART VIRUS VACCINE; ZALUTUMUMAB;

ADD ON THERAPY; AFRICAN AMERICAN; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CHROMOSOME ABERRATION; CLINICAL TRIAL; CPG ISLAND; CYTOGENETICS; DNA METHYLATION; DRUG POTENTIATION; DRUG WITHDRAWAL; EPIGENETICS; EPITHELIUM TUMOR; GENE SILENCING; GENOTYPE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH THROUGHPUT SCREENING; HUMAN; KARYOTYPE; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RACE; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

HUMAN PAPILLOMAVIRUS TYPE 16;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84864869456     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03262210     Document Type: Review

References (192)

1. National Cancer Institute. SEER cancer statistics review 1975-2006: Section 16: Melanoma of the skin [online]. Available from URL: Http://seer.cancer. gov/csr/1975-2006/ [Accessed 2012 Jun 27]
2. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004 Aug; 15 (8): 1179-86 (Pubitemid 39199304)
3. American Cancer Society Inc. Cancer facts & figures 2012. Atlanta (GA): American Cancer Society Inc., 2012 [online]. Available from URL: Http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancerfacts-figures-2012 [Accessed 2012 Jun 27]
4. Carvalho AL, Nishimoto IN, Califano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer 2005 May 1; 114 (5): 806-16 (Pubitemid 40344442)
5. Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007 May 16; 99 (10): 777-89 (Pubitemid 47073524)
6. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009 Feb; 18 (2): 541-50
7. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004 May 8; 363 (9420): 1488-9
8. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010 Jul 1; 363 (1): 24-35
9. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008 Feb 20; 100 (4): 261-9 (Pubitemid 351480538)
10. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: Ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005 Oct; 14 (10): 2287-93 (Pubitemid 41437826)
11. Onoda N, Nehmi A, Weiner D, et al. Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. Head Neck 2001 Oct; 23 (10): 860-70 (Pubitemid 32862290)
12. Hoffman HT, Karnell LH, Funk GF, et al. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998 Sep; 124 (9): 951-62 (Pubitemid 28411496)
13. Shavers VL, Harlan LC, Winn D, et al. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev 2003 Mar; 22 (1): 25-38 (Pubitemid 36363511)
14. Settle K, Taylor R, Wolf J, et al. Race impacts outcome in stage III/IV squamous cell carcinomas of the head and neck after concurrent chemoradiation therapy. Cancer 2009 Apr 15; 115 (8): 1744-52
15. Chernock RD, Zhang Q, El-Mofty SK, et al. Human papillomavirus-related squamous cell carcinoma of the oropharynx: A comparative study in Whites and African Americans. Arch Otolaryngol Head Neck Surg 2011 Feb; 137 (2): 163-9
16. Torres JB, Kittles RA. The relationship between 'race' and genetics in biomedical research. Curr Hypertens Rep 2007 Jun; 9 (3): 196-201 (Pubitemid 46894814)
17. Worsham MJ, Divine G, Kittles RA. Race as a social construct in head and neck cancer outcomes. Otolaryngol Head Neck Surg 2011 Mar; 144 (3): 381-9
18. Worsham MJ, Stephen JK, Lu M, et al. Disparate molecular, histopathology, and clinical factors in head and neck squamous cell carcinoma racial groups. Otolaryngol Head Neck Surg. Epub 2012 Mar 12
19. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953 Sep; 6 (5): 963-8
20. Koch WM, Boyle JO, Mao L, et al. p53 gene mutations as markers of tumor spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg 1994 Sep; 120 (9): 943-7 (Pubitemid 24287709)
21. Bedi GC, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: Evidence for a common clonal origin. Cancer Res 1996 Jun 1; 56 (11): 2484-7 (Pubitemid 26170678)
22. Worsham MJ, Wolman SR, Carey TE, et al. Common clonal origin of synchronous primary head and neck squamous cell carcinomas: Analysis by tumor karyotypes and fluorescence in situ hybridization. Hum Pathol 1995 Mar; 26 (3): 251-61
23. Patel SG, Shah JP. TNM staging of cancers of the head and neck: Striving for uniformity among diversity. CA Cancer J Clin 2005 Jul-Aug; 55 (4): 242-58; quiz 261-2, 264 (Pubitemid 41271230)
24. Someya M, Sakata K, Matsumoto Y, et al. The association of DNAdependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis 2006 Jan; 27 (1): 117-22 (Pubitemid 43025251)
25. Smiraglia DJ, Smith LT, Lang JC, et al. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 2003 Jan; 40 (1): 25-33 (Pubitemid 36115121)
26. Worsham MJ, Pals G, Schouten JP, et al. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003 Jul; 129 (7): 702-8 (Pubitemid 36858953)
27. Whang-Peng J, Banks-Schlegel SP, Lee EC. Cytogenetic studies of esophageal carcinoma cell lines. Cancer Genet Cytogenet 1990 Mar; 45 (1): 101-20 (Pubitemid 20101010)
28. Worsham MJ, Carey TE, Benninger MS, et al. Clonal cytogenetic evolution in a squamous cell carcinoma of the skin from a xeroderma pigmentosum patient. Genes Chromosomes Cancer 1993 Jul; 7 (3): 158-64 (Pubitemid 23194425)
29. Worsham MJ, Van Dyke DL, Grenman SE, et al. Consistent chromosome abnormalities in squamous cell carcinoma of the vulva. Genes Chromosomes Cancer 1991 Nov; 3 (6): 420-32
30. De Schutter H, Spaepen M, Mc Bride WH, et al. The clinical relevance of microsatellite alterations in head and neck squamous cell carcinoma: A critical review. Eur J Hum Genet 2007 Jul; 15 (7): 734-41 (Pubitemid 46969882)
31. Zhou X, Jordan RC, Li Y, et al. Frequent allelic imbalances at 8p and 11q22 in oral and oropharyngeal epithelial dysplastic lesions. Cancer Genet Cytogenet 2005 Aug; 161 (1): 86-9 (Pubitemid 41096057)
32. Coon SW, Savera AT, Zarbo RJ, et al. Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma. Int J Cancer 2004 Aug 20; 111 (2): 206-12 (Pubitemid 38930823)
33. Worsham MJ, Chen KM, Tiwari N, et al. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006 Apr; 132 (4): 409-15
34. Saglam O, Shah V, Worsham MJ. Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: An exploratory analysis. Diagn Mol Pathol 2007 Dec; 16 (4): 218-21 (Pubitemid 350196979)
35. Akervall J. Genomic screening of head and neck cancer and its implications for therapy planning. Eur Arch Otorhinolaryngol 2006 Apr; 263 (4): 297-304 (Pubitemid 43978736)
36. Worsham MJ, Wolman SR, Carey TE, et al. Chromosomal aberrations identified in culture of squamous carcinomas are confirmed by fluorescence in situ hybridisation. Mol Pathol 1999 Feb; 52 (1): 42-6 (Pubitemid 29064263)
37. Huang Q, Yu GP, McCormick SA, et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: Construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer 2002 Jun; 34 (2): 224-33 (Pubitemid 34578679)
38. Gotte K, Tremmel SC, Popp S, et al. Intratumoral genomic heterogeneity in advanced head and neck cancer detected by comparative genomic hybridization. Adv Otorhinolaryngol 2005; 62: 38-48
39. Carey TE, Frank CJ, Raval JR, et al. Identifying genetic changes associated with tumor progression in squamous cell carcinoma. Acta Otolaryngol Suppl 1997; 529: 229-32 (Pubitemid 27364405)
40. Buchhagen DL, Worsham MJ, Dyke DL, et al. Two regions of homozygosity on chromosome 3p in squamous cell carcinoma of the head and neck: Comparison with cytogenetic analysis. Head Neck 1996 Nov-Dec; 18 (6): 529-37 (Pubitemid 26349532)
41. Carey TE, Worsham MJ, Van Dyke DL. Chromosomal biomarkers in the clonal evolution of head and neck squamous neoplasia. J Cell Biochem Suppl 1993; 17F: 213-22 (Pubitemid 23252945)
42. Carey TE, Van Dyke DL, Worsham MJ. Nonrandom chromosome aberrations and clonal populations in head and neck cancer. Anticancer Res 1993 Nov-Dec; 13 (6B): 2561-7 (Pubitemid 24103306)
43. Bradford CR, Kimmel KA, Van Dyke DL, et al. 11p deletions and breakpoints in squamous cell carcinoma: Association with altered reactivity with the UM-E7 antibody. Genes Chromosomes Cancer 1991 Jul; 3 (4): 272-82
44. Carey TE, Van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res 1989 Nov 1; 49 (21): 6098-107 (Pubitemid 19274176)
45. Worsham MJ, Benninger MJ, Zarbo RJ, et al. Deletion 9p22-pter and loss of Y as primary chromosome abnormalities in a squamous cell carcinoma of the vocal cord. Genes Chromosomes Cancer 1993 Jan; 6 (1): 58-60 (Pubitemid 23047368)
46. Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994 Mar; 9 (3): 192-206 (Pubitemid 24074737)
47. Nemunaitis J, Nemunaitis J. Head and neck cancer: Response to p53-based therapeutics. Head Neck 2011 Jan; 33 (1): 131-4
48. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999 Apr 2; 97 (1): 53-61
49. Yarbrough WG. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope 2002 Dec; 112 (12): 2114-28 (Pubitemid 35417032)
50. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999 Oct; 5 (10): 2810-9 (Pubitemid 29493956)
51. Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004 Sep 1; 10 (17): 5684-91 (Pubitemid 39180943)
52. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007 Dec 1; 121 (11): 2465-72 (Pubitemid 350022416)
53. Modjtahedi H, Dean C. The receptor for EGF and its ligands - Expression, prognostic value and target for therapy in cancer (review). Int J Oncol 1994 Feb; 4 (2): 277-96 (Pubitemid 24039840)
54. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993 Aug 1; 53 (15): 3579-84 (Pubitemid 23229640)
55. OngkekoWM, Altuna X, Weisman RA, et al. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 2005 Jul; 124 (1): 71-6 (Pubitemid 40944376)
56. Sheu JJ, Hua CH, Wan L, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009 Mar 15; 69 (6): 2568-76
57. Kim S, Grandis JR, Rinaldo A, et al. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 2008 May; 30 (5): 667-74 (Pubitemid 351656109)
58. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998 Jun 3; 90 (11): 824-32 (Pubitemid 28280548)
59. Temam S,Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007 Jun 1; 25 (16): 2164-70 (Pubitemid 46954638)
60. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006 Sep 1; 24 (25): 4170-6 (Pubitemid 46622295)
61. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002 Dec 15; 62 (24): 7350-6 (Pubitemid 36025259)
62. Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl 1993; 17F: 188-91 (Pubitemid 23252940)
63. Grandis JR, Chakraborty A, Zeng Q, et al. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 1998 Apr 1; 69 (1): 55-62 (Pubitemid 28099922)
64. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002 Jun 15; 30 (12): E57
65. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011 Aug 26; 333 (6046): 1157-60
66. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011 Aug 26; 333 (6046): 1154-7
67. Costello JF, Plass C. Methylation matters. J Med Genet 2001 May; 38 (5): 285-303 (Pubitemid 32433981)
68. Li E, Bestor TH, Jaenisch R. Targetedmutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992 Jun 12; 69 (6): 915-26
69. Li E, Beard C, Jaenisch R. Role forDNA methylation in genomic imprinting. Nature 1993 Nov 25; 366 (6453): 362-5 (Pubitemid 23349366)
70. Pfeifer GP, Tanguay RL, Steigerwald SD, et al. In vivo footprint and methylation analysis by PCR-aided genomic sequencing: Comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1. Genes Dev 1990 Aug; 4 (8): 1277-87
71. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000 Feb; 24 (2): 132-8 (Pubitemid 30094712)
72. Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA- methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993 Aug 4; 85 (15): 1235-40 (Pubitemid 23223530)
73. Lin SY, Yeh KT, Chen WT, et al. Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer. Anticancer Res 2004 May-Jun; 24 (3a): 1645-50 (Pubitemid 38954689)
74. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-96 (Pubitemid 27435555)
75. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999 Feb; 21 (2): 163-7 (Pubitemid 29070360)
76. Chan MF, Liang G, Jones PA. Relationship between transcription and DNA methylation. Curr Top Microbiol Immunol 2000; 249: 75-86 (Pubitemid 30133494)
77. Worsham MJ, Stephen JK, Chen KM, et al. Delineating an epigenetic continuum in head and neck cancer. Cancer Lett. Epub 2012 Mar 1
78. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. AnnNY Acad Sci 2004 Jun; 1022: 40-3 (Pubitemid 38951579)
79. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004 Jun 15; 22 (12): 2363-70 (Pubitemid 41115393)
80. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004 Oct 15; 104 (8): 2492-8 (Pubitemid 39331852)
81. Olden K, Isaac L, Roberts L. Neighborhood-specific epigenome analysis: The pathway forward to understanding gene-environment interactions.NCMed J 2011 Mar-Apr; 72 (2): 125-7
82. Garber K. Breaking the silence: The rise of epigenetic therapy. J Natl Cancer Inst 2002 Jun 19; 94 (12): 874-5 (Pubitemid 34778082)
83. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003 Dec 3; 95 (23): 1747-57 (Pubitemid 38008897)
84. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 1999 Oct; 81 (4): 677-83 (Pubitemid 29458865)
85. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001 Apr 15; 61 (8): 3225-9 (Pubitemid 32695003)
86. Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001 Feb 1; 61 (3): 939-42 (Pubitemid 32174408)
87. Hasegawa M, Nelson HH, Peters E, et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002 Jun 20; 21 (27): 4231-6 (Pubitemid 34753829)
88. Viswanathan M, Tsuchida N, Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1,MGMTand E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003 May 20; 105 (1): 41-6 (Pubitemid 36418483)
89. El-Naggar AK, Lai S, Clayman G, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997 Dec; 151 (6): 1767-74 (Pubitemid 27527939)
90. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000 Feb 15; 60 (4): 892-5 (Pubitemid 30129522)
91. Chen K, Sawhney R, Khan M, et al. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2007 Nov; 133 (11): 1131-8 (Pubitemid 350157026)
92. Zou CP, Youssef EM, Zou CC, et al. Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells. Oncogene 2001 Oct 18; 20 (47): 6820-7 (Pubitemid 33052172)
93. Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994 Jul 1; 54 (13): 3580-7 (Pubitemid 24225987)
94. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990 Oct 1; 50 (19): 6119-29 (Pubitemid 20323662)
95. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998 Aug; 153 (2): 333-9 (Pubitemid 28373643)
96. Stephen JK, Chen KM, Shah V, et al. DNA hypermethylation markers of poor outcome in laryngeal cancer. Clin Epigenetics 2010 Sep 1; 1 (1-2): 61-9
97. Stephen JK, SymaLM, Chen KM, et al.Molecular characterization of late stomal recurrence following total laryngectomy
98. Stephen JK, Vaught LE, Chen KM, et al. Epigenetic events underlie the pathogenesis of sinonasal papillomas. Mod Pathol 2007 Oct; 20 (10): 1019-27 (Pubitemid 47429202)
99. Stephen JK, Vaught LE, Chen KM, et al. An epigenetically derived monoclonal origin for recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2007 Jul; 133 (7): 684-92 (Pubitemid 47080421)
100. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000 May 3; 92 (9): 709-20 (Pubitemid 30365531)
101. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007 May 10; 356 (19): 1944-56 (Pubitemid 46740304)
102. Chen AA, Marsit CJ, Christensen BC, et al. Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. Carcinogenesis 2009 Jun; 30 (6): 977-81
103. Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010; 2: 15
104. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005 Feb; 14 (2): 467-75 (Pubitemid 40270113)
105. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004 Dec; 31 (6): 744-54 (Pubitemid 39602680)
106. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004 Nov; 78 (21): 11451-60 (Pubitemid 39390733)
107. Nguyen M, Song S, Liem A, et al. A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol 2002 Dec; 76 (24): 13039-48 (Pubitemid 35386988)
108. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003 Nov 10; 107 (3): 394-400 (Pubitemid 37266459)
109. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006 Dec 20; 24 (36): 5630-6 (Pubitemid 46631302)
110. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006 Feb 1; 12 (3 Pt 1): 701-9 (Pubitemid 43259848)
111. Smith EM, Wang D, Kim Y, et al. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol 2008 Feb; 44 (2): 133-42 (Pubitemid 351179656)
112. Ragin CC, Taioli E, Weissfeld JL, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 2006 Nov 20; 95 (10): 1432-8 (Pubitemid 44760098)
113. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990 Dec 21; 63 (6): 1129-36 (Pubitemid 120035062)
114. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995 Dec; 1 (12): 1245-6
115. Haupt Y, Robles AI, Prives C, et al. Deconstruction of p53 functions and regulation. Oncogene 2002 Nov 28; 21 (54): 8223-31 (Pubitemid 35477862)
116. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004 Jul 7; 96 (13): 998-1006 (Pubitemid 39162642)
117. Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002 Feb 28; 21 (10): 1510-7 (Pubitemid 34226138)
118. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001 Jul 15; 93 (2): 232-5 (Pubitemid 32574279)
119. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cancer worldwide: A meta-analysis. Br J Cancer 2003; 88: 63-73
120. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: New online mutation analysis and recommendations to users. HumMutat 2002; 19: 607-14 (Pubitemid 34556481)
121. Dai M, Clifford GM, le Calvez F, et al., IARC Multicenter Oral Cancer Study Group. Human papillomavirus type 16 and TP53 mutation in oral cancer: Matched analysis of the IARC multicenter study. Cancer Res 2004; 64 (2): 468-71 (Pubitemid 38120884)
122. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996 Jun 1; 56 (11): 2488-92 (Pubitemid 26170679)
123. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006 Apr 20; 25 (17): 2558-64
124. Dahlgren L, Mellin H, Wangsa D, et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003 Nov 1; 107 (2): 244-9 (Pubitemid 37152904)
125. Martinez I, Wang J, Hobson KF, et al. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007 Jan; 43 (2): 415-32 (Pubitemid 46123982)
126. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. Natl Cancer Inst 2003; 95: 1772-83 (Pubitemid 38008900)
127. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995 Mar 16; 332 (11): 712-7
128. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008 Mar 19; 100 (6): 407-20 (Pubitemid 351480511)
129. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009 Nov; 135 (11): 1137-46
130. National Cancer Institute (NCI). Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer [ClinicalTrials. gov identifier NCT01302834]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: Http://clinicaltrials.gov/ct2/show/ NCT01302834 [Accessed 2012 Jun 27]
131. Schwartz SR, Yueh B, McDougall JK, et al. Human papillomavirus infection and survival in oral squamous cell cancer: A population-based study. Otolaryngol Head Neck Surg 2001; 125 (1): 1-9 (Pubitemid 33661083)
132. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006 Feb 10; 24 (5): 736-47 (Pubitemid 46622040)
133. Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol 2010 Aug; 11 (8): 781-9
134. Mydlarz WK, Hennessey PT, Califano JA. Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin Med Diagn 2010 Jan 1; 4 (1): 53-65
135. Carter CA, Kelly RJ, Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 2009 Dec; 18 (12): 1829-42
136. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000 Jun; 6 (6): 2166-74 (Pubitemid 30399181)
137. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002 May; 1 (7): 507-14
138. Vincenzi B, Zoccoli A, Pantano F, et al. Cetuximab: from bench to bedside. Curr Cancer Drug Targets 2010 Feb; 10 (1): 80-95
139. Lopez-Albaitero A, Lee SC, Morgan S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009 Nov; 58 (11): 1853-64
140. Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010 Sep; 15 (3): 355-73
141. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004 Jan 1; 22 (1): 77-85 (Pubitemid 41095117)
142. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 2007 Jun 1; 25 (16): 2178-83 (Pubitemid 46954640)
143. Henry Ford Health System. Erlotinib (Tarceva) during first line standard platinum containing chemo for advanced squamous cell head and neck cancer [ClinicalTrials.gov identifier NCT00448240]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://clinical trials.gov/ct2/show/NCT00448240 [Accessed 2012 Jun 27]
144. Hoffmann-La Roche. A study of Tarceva (erlotinib) in patients with resected head and neck squamous cell cancer [ClinicalTrials.gov identifier NCT00412217]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://clinicaltrials.gov/ct2/show/NCT00412217 [Accessed 2012 Jun 27]
145. MD Anderson Cancer Center. Erlotinib prevention of oral cancer (EPOC) [ClinicalTrials.gov identifier NCT00402779]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://clinical trials.gov/ct2/show/NCT00402779 [Accessed 2012 Jun 27]
146. Del Campo JM, Hitt R, Sebastian P, et al. Effects of lapatinib monotherapy: Results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011 Aug 23; 105 (5): 618-27
147. GlaxoSmithKline. Study of adjuvant lapatinib in high-risk head and neck cancer subjects after surgery [ClinicalTrials.gov identifier NCT00424255]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://clinicaltrials.gov/ct2/show/NCT00424255 [Accessed 2012 Jun 27]
148. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis. Clin Cancer Res 2005 Feb 15; 11 (4): 1434-40 (Pubitemid 40315223)
149. Shang ZJ, Li ZB, Li JR. VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: In vitro and in vivo studies. Int J Oral Maxillofac Surg 2006 Jun; 35 (6): 533-8
150. Liang X, Yang D, Hu J, et al. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/ angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008 May-Jun; 28 (3A): 1659-66 (Pubitemid 351892941)
151. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004 May; 3 (5): 391-400 (Pubitemid 38618122)
152. Stein MN, Flaherty KT. CCR drug updates: Sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007 Jul 1; 13 (13): 3765-70 (Pubitemid 47037579)
153. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2007 Jul 10; 28 (20): 3330-5
154. Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2009 Oct; 28 (5): 677-83
155. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010 Jan 1; 28 (1): 21-8
156. Moral M, Paramio JM. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008 Oct; 23 (10): 1269-78
157. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77 (6): 400-10
158. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: A potential target for UCN-01. Clin Cancer Res 2004 Jun 15; 10 (12 Pt 1): 4029-37 (Pubitemid 38812478)
159. Amornphimoltham P, Leelahavanichkul K, Molinolo A, et al. Inhibition of mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. Clin Cancer Res 2008 Dec 15; 14 (24): 8094-101
160. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008 Jul; 62 (2): 305-13 (Pubitemid 351692089)
161. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006 Jun 10; 24 (17): 2606-11 (Pubitemid 46622080)
162. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in Black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009 Sep; 2 (9): 776-81
163. University of Maryland. MAGE-A3/HPV 16 vaccine for squamous cell carcinoma of the head and neck [ClinicalTrials.gov identifier NCT00257738]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http://clinicaltrials.gov/ct2/show/NCT00257738 [Accessed 2012 Jun 27]
164. University of Maryland. Four doses of MAGE vaccine for patients with squamous cell carcinoma of the head and neck [ClinicalTrials.gov identifier NCT00704041]. US National Institutes of Health, ClinicalTrials.gov [online] Available from URL: Http://clinicaltrials.gov/ct2/show/NCT00704041 [Accessed 2012 Jun 27]
165. Baleja JD, Cherry JJ, Liu Z, et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 2006 Oct; 72 (1): 49-59 (Pubitemid 44291470)
166. Jung SO, Ro HS, Kho BH, et al. Surface plasmon resonance imaging-based protein arrays for high-throughput screening of protein-protein interaction inhibitors. Proteomics 2005 Nov; 5 (17): 4427-31 (Pubitemid 41739920)
167. Sterlinko Grm H, Weber M, Elston R, et al. Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J Mol Biol 2004 Jan 23; 335 (4): 971-85 (Pubitemid 38091604)
168. Beerheide W, Bernard HU, Tan YJ, et al. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J Natl Cancer Inst 1999 Jul 21; 91 (14): 1211-20 (Pubitemid 29357187)
169. Butz K, Denk C, Ullmann A, et al. Induction of apoptosis in human papillomavirus positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A 2000 Jun 6; 97 (12): 6693-7 (Pubitemid 30412776)
170. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade withC225modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999 Apr 15; 59 (8): 1935-40 (Pubitemid 29186168)
171. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000 Feb; 6 (2): 701-8 (Pubitemid 30111496)
172. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 Feb 9; 354 (6): 567-78 (Pubitemid 43209104)
173. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010 Jan; 11 (1): 21-8
174. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008 May 17; 371 (9625): 1695-709 (Pubitemid 351671886)
175. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.NEngl JMed 2008 Sep 11; 359 (11): 1116-27
176. Hong A, Dobbins T, Lee CS, et al. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer 2010 Jul; 46 (11): 2088-96
177. National Cancer Institute (NCI). Radiation therapy and cisplatin with or without cetuximab in treating patients with stage III or stage IV head and neck cancer [ClinicalTrials.gov identifier NCT00265941]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: Http:// clinicaltrials.gov/ct2/show/NCT00265941 [Accessed 2012 Jun 28]
178. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009 Apr 10; 27 (11): 1864-71
179. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007 May 15; 13 (10): 2890-6 (Pubitemid 46849563)
180. Moore MJ, Goldstein D, HammJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 May 20; 25 (15): 1960-6 (Pubitemid 46972777)
181. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007 Apr; 7 (4): 295-308 (Pubitemid 46480970)
182. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 Apr 15; 66 (8): 3992-5
183. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007 Apr 23; 96 (8): 1166-9 (Pubitemid 46625066)
184. Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010; 10: 189
185. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 2008 Mar 1; 14 (5): 1291-5 (Pubitemid 351413906)
186. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007 Oct; 33 (6): 565-77 (Pubitemid 47355341)
187. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007 Jul 1; 13 (13): 3855-9 (Pubitemid 47037591)
188. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008 Jul 8; 99 (1): 167-72 (Pubitemid 351920246)
189. Hayes M, Lan C, Yan J, et al. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 2011 Dec; 31 (12): 4135-9
190. Richards KL, Zhang B, Baggerly KA, et al. Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS ONE 2009; 4 (3): E4941
191. Lu D, Hoory T, Monie A, et al. Treatment with demethylating agent, 5-aza-20-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009 Jul 9; 27 (32): 4363-9
192. Nicolson GL. Bioregulators come of age in the control of tumor growth and metastasis. J Natl Cancer Inst 1996 Apr 17; 88 (8): 479-80